JP2022532534A5 - - Google Patents
Info
- Publication number
- JP2022532534A5 JP2022532534A5 JP2021565875A JP2021565875A JP2022532534A5 JP 2022532534 A5 JP2022532534 A5 JP 2022532534A5 JP 2021565875 A JP2021565875 A JP 2021565875A JP 2021565875 A JP2021565875 A JP 2021565875A JP 2022532534 A5 JP2022532534 A5 JP 2022532534A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001728A JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906685.1A GB201906685D0 (en) | 2019-05-13 | 2019-05-13 | Activatable protein constructs and uses thereof |
| GB1906685.1 | 2019-05-13 | ||
| GBGB1910254.0A GB201910254D0 (en) | 2019-05-13 | 2019-07-17 | Activatable protein constructs and uses thereof |
| GB1910254.0 | 2019-07-17 | ||
| GBGB1917678.3A GB201917678D0 (en) | 2019-05-13 | 2019-12-04 | Activatable protein constructs and uses thereof |
| GB1917678.3 | 2019-12-04 | ||
| GBGB2001196.1A GB202001196D0 (en) | 2019-05-13 | 2020-01-28 | Activatable protein constructs and uses thereof |
| GB2001196.1 | 2020-01-28 | ||
| PCT/EP2020/063362 WO2020229553A1 (en) | 2019-05-13 | 2020-05-13 | Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Division JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532534A JP2022532534A (ja) | 2022-07-15 |
| JPWO2020229553A5 JPWO2020229553A5 (https=) | 2023-05-22 |
| JP2022532534A5 true JP2022532534A5 (https=) | 2023-05-22 |
| JP7617027B2 JP7617027B2 (ja) | 2025-01-17 |
Family
ID=67384589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565875A Active JP7617027B2 (ja) | 2019-05-13 | 2020-05-13 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001728A Pending JP2025039660A (ja) | 2019-05-13 | 2025-01-06 | ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192899A1 (https=) |
| EP (1) | EP3969116A1 (https=) |
| JP (2) | JP7617027B2 (https=) |
| KR (1) | KR20220008841A (https=) |
| CN (2) | CN113840634B (https=) |
| AU (1) | AU2020276891A1 (https=) |
| BR (1) | BR112021022661A2 (https=) |
| CA (1) | CA3138827A1 (https=) |
| GB (4) | GB201906685D0 (https=) |
| IL (1) | IL287890A (https=) |
| MX (1) | MX2021013844A (https=) |
| SG (1) | SG11202112114YA (https=) |
| WO (1) | WO2020229553A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| JP2023547499A (ja) * | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Ｆｃ変異体 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023144423A1 (en) * | 2022-01-31 | 2023-08-03 | LockBody Therapeutics Ltd | Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof |
| CA3246893A1 (en) * | 2022-03-30 | 2023-10-05 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CA3251998A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| GB202302074D0 (en) * | 2023-02-14 | 2023-03-29 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2024218512A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof |
| WO2024218509A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof |
| KR20250088543A (ko) * | 2023-05-19 | 2025-06-17 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN121866269A (zh) * | 2023-09-14 | 2026-04-14 | Abl生物公司 | 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法 |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2352763T5 (pl) * | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| KR102499191B1 (ko) * | 2016-03-18 | 2023-02-13 | 프레드 허친슨 캔서 센터 | Cd20 면역요법을 위한 조성물 및 방법 |
| CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
| AU2018250641B2 (en) * | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2019
- 2019-05-13 GB GBGB1906685.1A patent/GB201906685D0/en not_active Ceased
- 2019-07-17 GB GBGB1910254.0A patent/GB201910254D0/en not_active Ceased
- 2019-12-04 GB GBGB1917678.3A patent/GB201917678D0/en not_active Ceased
-
2020
- 2020-01-28 GB GBGB2001196.1A patent/GB202001196D0/en not_active Ceased
- 2020-05-13 BR BR112021022661A patent/BR112021022661A2/pt unknown
- 2020-05-13 AU AU2020276891A patent/AU2020276891A1/en active Pending
- 2020-05-13 WO PCT/EP2020/063362 patent/WO2020229553A1/en not_active Ceased
- 2020-05-13 KR KR1020217038644A patent/KR20220008841A/ko active Pending
- 2020-05-13 EP EP20726749.3A patent/EP3969116A1/en active Pending
- 2020-05-13 CA CA3138827A patent/CA3138827A1/en active Pending
- 2020-05-13 CN CN202080034818.9A patent/CN113840634B/zh active Active
- 2020-05-13 SG SG11202112114YA patent/SG11202112114YA/en unknown
- 2020-05-13 US US17/610,899 patent/US20230192899A1/en active Pending
- 2020-05-13 MX MX2021013844A patent/MX2021013844A/es unknown
- 2020-05-13 CN CN202510701821.6A patent/CN120554533A/zh active Pending
- 2020-05-13 JP JP2021565875A patent/JP7617027B2/ja active Active
-
2021
- 2021-11-07 IL IL287890A patent/IL287890A/en unknown
-
2025
- 2025-01-06 JP JP2025001728A patent/JP2025039660A/ja active Pending